Dopavision Appoints Prof. Dr. Jens Ellrich as Chief Scientific Officer
21 mars 2023 05h00 HE
|
AKAMPION
- Leading translational medicine and neuroscience expert to head Dopavision’s research activities Berlin, Germany, March 21, 2023 --- Dopavision, a clinical-stage company pioneering the...
Cellbox Solutions Raises EUR 6.5 Million in Series A1 Financing Round
07 mars 2023 04h00 HE
|
AKAMPION
- CK Ventures, Fraunhofer Ventures, NRW.Venture and Fil Bros join forces with renowned private investors- Planned expansion of US business and launch of tailored cell therapy shipment solutions ...
Evonik and BellaSeno advance commercialization of 3D-printed, bioresorbable implants
06 mars 2023 04h00 HE
|
AKAMPION
Expanded partnership of two leading innovatorsResomer® used in commercial 3D-printed implants for both soft and hard tissue applicationsBellaSeno receives market authorization for fully resorbable...
Pan Cancer T Appoints Prof. Dr. Chiara Bonini to its Scientific Advisory Board
23 févr. 2023 04h00 HE
|
AKAMPION
- Leading European T cell therapy researcher adds further scientific expertise ROTTERDAM, February 23, 2023 - Pan Cancer T B.V., a biotech spin-off from Erasmus MC dedicated to the discovery...
Rewind Therapeutics Raises Additional Funding and Adds Sunstone Life Science Ventures A/S as New Investor
25 janv. 2023 04h00 HE
|
AKAMPION
- Claus Andersson, PhD, joins Rewind´s Board of Directors Leuven, Belgium, January 25, 2023 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated...
ImmunOs Therapeutics Receives Regulatory Approval for First-In-Human Trial of IOS-1002
17 janv. 2023 04h00 HE
|
AKAMPION
- Lead compound IOS-1002 to be studied as mono and combination therapy in patients with advanced solid tumors- First patients to be enrolled in Q1, 2023 Schlieren (Zurich Area), Switzerland –...
Pan Cancer T Appoints Dr. Rachel Abbott as Chief Scientific Officer
17 janv. 2023 04h00 HE
|
AKAMPION
- Strengthening of T cell research expertise to develop next-generation T cell therapies for patients with limited or no treatment options ROTTERDAM, January 17, 2023 - Pan Cancer T B.V., a...
1ST Biotherapeutics, Inc., Announces FDA Clearance of IND Application for Phase 1/2 Study of FB849 to Treat Patients with Advanced Solid Tumors
13 déc. 2022 04h00 HE
|
AKAMPION
- Initiation of Phase 1/2 Clinical Trial Expected in Q1 2023 YONGIN, South Korea, December 13, 2022 -- 1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development...
Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team
29 nov. 2022 04h00 HE
|
AKAMPION
- Former GlaxoSmithKline and Proximagen executive adds to Rewind´s drug discovery and development expertise Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing...
HpVac Appoints Joana Vitte, MD, PhD, as Chief Scientific Officer
23 nov. 2022 04h00 HE
|
AKAMPION
- Significant expansion of allergy research expertise Geneva, Switzerland, November 23, 2022 – HpVac SA, a company developing novel preventive and therapeutic first-line therapies against...